Report: Light Sciences Oncology readies cuts as cancer program flunks late-stage test; Novavax touts RSV vax study results;

@FierceBiotech: AZ's MedImmune signs agreement with Pfizer for tremelimumab, a CTLA-4 monoclonal antibody that's a potential cancer treatment. Story | Follow @FierceBiotech

@ JohnCFierce: Mymetics "reclaims" flu vax from Solvay. $MYMX stock plunges 25% on the score, which means a loss of one cent. Release | Follow @JohnCFierce

@RyanMFierce: I caught up with four cool life sciences tech outfits with ties to the Boston area for my companies-to-watch report. Story | Follow @RyanMFierce

@MaureenFierce: Influenza pandemic prompts EMA vaccine quality rethink. Item | Follow @MaureenFierce

Xconomy's Luke Timmerman reports that Seattle-based Light Sciences Oncology's long running, late-stage program for a drug/device cancer treatment ended in failure, laying the stage for deep budget cuts which will include layoffs. Report

> MedImmune has licensed the rights to tremelimumab, one of Pfizer's cancer treatments. Story

> Novavax says that its RSV vaccine performed well in a study involving 150 patients. "The clinical data from this trial now provides a pathway for us to aggressively move forward in studying this vaccine candidate in infants, young children and older adults," Chief Executive Stanley Erck said. Report

> Ann Arbor-based Lycera named Kathleen M. Metters as president and CEO. She is the former senior vice president and head of worldwide basic research at Merck. Lycera release

> Emergent BioSolutions has won a contract worth up to $1.25 billion for deliveries of its BioThrax anthrax vaccine. Story

> Switzlerland's Mymetics says that it has reclaimed its influenza vaccine from Solvay, saying that Solvay had had to reprioritize its pipeline after the sale of Solvay Biologics to Abbott in 2010. Mymetics release

Pharma News

@FiercePharma: Merck's Fosamax-suit score hits 3-1: Juries find for $MRK in all but one bellwether case. News | Follow @FiercePharma

> Pharma group may securitize Spain's unpaid drug bills. Report

> Germany's Stada amenable to merger of equals. Article

> Merck prevails in fourth Fosamax trial. News

> 'Lake Wobegon' effect to blame for spiraling CEO pay. Piece

> Hikma moves into Morocco with $111M deal. Item

Manufacturing News

> DHL, pharma group assess India's hobbled logistics. Story

> Hill Dermaceuticals enters consent decree with FDA. News

> Novo to enhance insulin in manufacturing/marketing strategy. Report

> Boehringer to launch biosimilars unit. Item

> FDA: Product quality issues fuel rise in drug shortages. Story

> Lonza readies as pharma sector boosts Singapore production. Article

Biotech Research News

> Pioneering Scripps scientist devotes a lifetime to addiction vaccines. Piece

> New mouse models open a window on autism research. Report

> Controversial XMRV study author fired from research post. More

> NIH kicks off $110M Knockout Mouse Project. Article

> Targeted treatment clears glioblastoma tumors in drug-resistant models. Story

> GSK's epigenetics team tests promising leukemia drug in mice. Item

And Finally... Incidences of throat cancer linked to HPV have soared in men in recent years. And it's on track to become more commonplace than cervical cancer caused by HPV. Story

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.